Prothrombin complex concentrate versus recombinant factor vIIa for reversal of hemodilutional coagulopathy in a porcine trauma model

Journal of Trauma - Injury, Infection and Critical Care

Volumn 68, Issue 5, 2010, Pages 1151-1157

  Dickneite, Gerhard ^a   Dörr, Bärbel ^a   Kaspereit, Franz ^a   Tanaka, Kenichi A ^b  

^a CSL BEHRING GMBH   (Germany)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Animal; Blood coagulation disorders; Hemodilution; Models; Prothrombin complex concentrates; Recombinant factor VIIa; Thrombin generation

Indexed keywords

BERIPLEX; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; HETASTARCH; ISOTONIC SOLUTION; PROTHROMBIN; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL PH; ARTICLE; BLOOD CLOTTING DISORDER; BLOOD VOLUME; CONTROLLED STUDY; DRUG MECHANISM; ERYTHROCYTE COUNT; HEMODILUTION; HEMOSTASIS; IN VIVO STUDY; MALE; NONHUMAN; PILOT STUDY; PRIORITY JOURNAL; PROTHROMBIN TIME; SPLEEN INJURY; SWINE; THROMBIN TIME; THROMBOCYTE COUNT;

ANIMALS; BLOOD COAGULATION DISORDERS; BLOOD COAGULATION FACTORS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FACTOR VIIA; FLUID THERAPY; HEMODILUTION; HEMORRHAGE; HEMOSTASIS; KAPLAN-MEIERS ESTIMATE; MALE; PILOT PROJECTS; PROTHROMBIN TIME; RECOMBINANT PROTEINS; RESUSCITATION; SPLEEN; STATISTICS, NONPARAMETRIC; SWINE; TIME FACTORS; TREATMENT OUTCOME; WOUNDS AND INJURIES;

EID: 77952254938     PISSN: 00225282     EISSN: 15298809     Source Type: Journal    
DOI: 10.1097/TA.0b013e3181b06364     Document Type: Article

References (38)

1. Kauvar DS, Wade CE. The epidemiology and modern management of traumatic hemorrhage: US and international perspectives. Crit Care. 2005;9(Suppl 5): S1-S9.
2. Spahn DR, Cerny V, Coats TJ, et al. Management of bleeding following major trauma: a European guideline. Crit Care. 2007;11:R17.
3. Hess JR. Blood and coagulation support in trauma care. Hematology Am Soc Hematol Educ Program. 2007:187-191.
4. O'Shaughnessy DF, Atterbury C, Bolton Maggs P, et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol. 2004;126:11-28.
5. Gonzalez EA, Moore FA, Holcomb JB, et al. Fresh frozen plasma should be given earlier to patients requiring massive transfusion. J Trauma. 2007;62:112-119.
6. Boffard KD, Riou B, Warren B, et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma. 2005;59:8-15.
7. ®): current development. Vox Sang. 2007;92:281-288.
8. Schreiber MA, Holcomb JB, Rojkjaer R. Preclinical trauma studies of recombinant factor VIIa. Crit Care. 2005;9(Suppl 5): S25-S28.
9. Fries D, Haas T, Klingler A, et al. Efficacy of fibrinogen and prothrombin complex concentrate used to reverse dilutional coagulopathy-a porcine model. Br J Anaesth. 2006;97:460-467.
10. Dickneite G, Doerr B, Kaspereit F. Characterization of the coagulation deficit in porcine dilutional coagulopathy and substitution with a prothrombin complex concentrate. Anesth Analg. 2008;106:1070-1077.
11. Dickneite G. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of coumarin anticoagulation. Thromb Res. 2007;119:643-651.
12. Dickneite G, Pragst I. Prothrombin complex concentrate vs fresh frozen plasma for reversal of dilutional coagulopathy in a porcine trauma model. Br J Anaesth. 2009;102:345-354.
13. ® P/N: Erhöhung der Kapazität zur Viruseliminierung unter Beibehaltung der Produktqualität. Beitr Infusionsther Transfusionsmed. 1996;33:220-224.
14. Weimer T, Streichert S, Watson C, Gröner A. High-titer screening PCR: a successful strategy for reducing the parvovirus B19 load in plasma pools for fractionation. Transfusion. 2001;41:1500-1504.
15. Chandra S, Groener A, Feldman F. Effectiveness of alternative treatments for reducing potential viral contaminants from plasma-derived products. Thromb Res. 2002;105:391-400.
16. Ostermann H, Haertel S, Knaub S, Kalina U, Jung K, Pabinger I. Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers. Thromb Haemost. 2007;98:790-797.
17. Hemker HC, Giesen P, Al Dieri R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003;33:4-15.
18. Rossaint R, Duranteau J, Stahel PF, Spahn DR. Nonsurgical treatment of major bleeding. Anesthesiol Clin. 2007;25:35-48.
19. Holcomb JB. Use of recombinant activated factor VII to treat the acquired coagulopathy of trauma. J Trauma. 2005;58:1298-1303.
20. Rizoli SB, Nascimento B Jr, Osman F, et al. Recombinant activated coagulation factor VII and bleeding trauma patients. J Trauma. 2006;61:1419-1425.
21. Franchini M, Lippi G, Franchi M. The use of recombinant activated factor VII in obstetric and gynaecological haemorrhage. BJOG. 2007;114:8-15.
22. Jeroukhimov I, Jewelewicz D, Zaias J, et al. Early injection of high-dose recombinant factor VIIa decreases blood loss and prolongs time from injury to death in experimental liver injury. J Trauma. 2002;53:1053-1057.
23. Lynn M, Jerokhimov I, Jewelewicz D, et al. Early use of recombinant factor VIIa improves mean arterial pressure and may potentially decrease mortality in experimental hemorrhagic shock: a pilot study. J Trauma. 2002;52:703-707.
24. Klemcke HG, Delgado A, Holcomb JB, et al. Effect of recombinant FVIIa in hypothermic, coagulopathic pigs with liver injuries. J Trauma. 2005;59:155-161.
25. Howes DW, Stratford A, Stirling M, Ferri CC, Bardell T. Administration of recombinant factor VIIa decreases blood loss after blunt trauma in noncoagulopathic pigs. J Trauma. 2007;62:311-315.
26. Martinowitz U, Holcomb JB, Pusateri AE, et al. Intravenous rFVIIa administered for hemorrhage control in hypothermic coagulopathic swine with grade V liver injuries. J Trauma. 2001;50:721-729.
27. Schreiber MA, Holcomb JB, Hedner U, Brundage SI, Macaitis JM, Hoots K. The effect of recombinant factor VIIa on coagulopathic pigs with grade V liver injuries. J Trauma. 2002;53:252-257.
28. Sondeen JL, Pusateri AE, Hedner U, Yantis LD, Holcomb JB. Recombinant factor VIIa increases the pressure at which rebleeding occurs in porcine uncontrolled aortic hemorrhage model. Shock. 2004;22:163-168.
29. Pusateri AE, Ryan KL, Delgado AV, et al. Effects of increasing doses of activated recombinant factor VII on haemostatic parameters in swine. Thromb Haemost. 2005;93:275-283.
30. Spinella PC, Perkins JG, McLaughlin DF, et al. The effect of recombinant activated factor VII on mortality in combat-related casualties with severe trauma and massive transfusion. J Trauma. 2008;64:286-293.
31. Tanaka KA, Szlam F, Dickneite G, Levy JH. Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced anticoagulation. Thromb Res. 2008;122:117-123.
32. Hemker HC, Al Dieri R, De Smedt E, Béguin S. Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost. 2006;96:553-561.
33. Rodewald L, Scharrer I. Protein chemical investigation of 30 consecutive lots of double-virus eliminated PCC (Beriplex P/N) and summary of safety data. Hämostaseologie. 2004;24:A46.
34. O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA. 2006;295:293-298.
35. Martinowitz U, Michaelson M. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force. J Thromb Haemost. 2005;3:640-648.
36. Mathew P, Simon TL, Hunt KE, Crookston KP. How we manage requests for recombinant factor VIIa (NovoSeven). Transfusion. 2007;47:8-14.
37. Morris S, Ridley S, Munro V, Christensen MC. Cost effectiveness of recombinant activated factor VII for the control of bleeding in patients with severe blunt trauma injuries in the United Kingdom. Anaesthesia. 2007;62:43-52.
38. Steiner T, Rosand J, Diringer M. Intracerebral hemorrhage associated with oral anticoagulant therapy: current practices and unresolved questions. Stroke. 2006;37:256-262.